CYDY CytoDyn

CytoDyn to Hold 2020 Virtual Annual Meeting of Stockholders on September 30, 2020

CytoDyn to Hold 2020 Virtual Annual Meeting of Stockholders on September 30, 2020

VANCOUVER, Washington, Sept. 29, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, reminds investors today the 2020 Virtual Annual Meeting of Stockholders will be held at 9:30 am PT on September 30, 2020. As stated in the Company’s proxy statement dated September 1, 2020, due to public health concerns relating to the coronavirus pandemic, stockholders will not be able to attend the Annual Meeting in person. The Company provides the following information as a reminder on how stockholders and guests can participate in the virtual meeting format:

Time: 9:30 am PT

Webcast login:

Stockholder questions: Submitted online via the meeting link, passcode CYDY2020 and their individual control number noted on their proxy card. Guests will not be able to submit questions during the meeting.

At the conclusion of the business portion of the meeting, Nader Pourhassan, Ph.D., President and Chief Executive Officer, will present an overview of the Company via a slide deck, which will be available on the Company’s website () at 9:30 am PT. In light of the limited amount of time for the meeting, stockholders are also encouraged to submit questions to management before 8:00 am PT tomorrow to: .

CYTODYN CONTACTS

Investors:

Michael Mulholland

Office: 360.980.8524, ext. 102

EN
29/09/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on CytoDyn

 PRESS RELEASE

CytoDyn to Present at the H.C. Wainwright 27th Annual Global Investmen...

CytoDyn to Present at the H.C. Wainwright 27th Annual Global Investment Conference VANCOUVER, Washington, Aug. 28, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage biotechnology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple indications, today announced that management will participate in the H.C. Wainwright 27th Annual Global Investment Conference being held September 8 to 10, 2025, at the Lotte New York Palace Hotel in New York City. Rob...

 PRESS RELEASE

CytoDyn Announces Encouraging Survival Data in Patients with Metastati...

CytoDyn Announces Encouraging Survival Data in Patients with Metastatic Colorectal Cancer Previously Treated with Leronlimab Positive results in patients with advanced mCRC emphasize potential significance of CytoDyn’s ongoing Phase II CRC trial Dr. Benjamin Weinberg to present final results at the ESMO Gastrointestinal Cancers Congress 2025 in Barcelona, Spain VANCOUVER, Washington, July 01, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic in...

 PRESS RELEASE

CytoDyn Announces First Patient Dosed in Phase II Oncology Trial in Co...

CytoDyn Announces First Patient Dosed in Phase II Oncology Trial in Colorectal Cancer Enrollment is now underway across multiple clinical sites, in partnership with Syneos Health VANCOUVER, Washington, June 24, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced that the first patient has been dosed in the Company’s clinical trial evaluating the efficacy of leronlimab in patients with relapsed/refractory microsatellite st...

 PRESS RELEASE

CytoDyn Releases ESMO Breast Cancer Meeting Poster

CytoDyn Releases ESMO Breast Cancer Meeting Poster VANCOUVER, Washington, May 15, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today shared the Company’s poster presented at the European Society for Medical Oncology’s (“ESMO”) Breast Cancer meeting on May 14-17, 2025, in Munich, Germany. A copy of the poster is available at the following link: More information about the data CytoDyn presented at ESMO suggesting the novel mechanis...

 PRESS RELEASE

CytoDyn Announces Data Suggesting Novel Mechanism of Action of Leronli...

CytoDyn Announces Data Suggesting Novel Mechanism of Action of Leronlimab for the Treatment of Solid Tumors Survival observations in mTNBC patients correlated with increased PD-L1 expression Preliminary evidence suggests leronlimab has potential to turn “cold” tumors “hot” VANCOUVER, Washington, May 13, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced new data suggesting a novel mechanism of action of leronlimab for th...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch